| Why carry out this study? |
| Obesity has been shown to negatively affect the effectiveness of some rheumatoid arthritis (RA) treatments; in addition, some RA treatments are associated with weight gain. |
| This post hoc analysis of the FINCH 1–3 studies was conducted to assess the effect of filgotinib on the body mass index (BMI) of patients with RA and to evaluate the efficacy and safety of filgotinib according to baseline BMI. |
| What was learned from the study? |
| Filgotinib did not substantially change the BMI in patients with RA. |
| Baseline BMI did not appear to affect the efficacy of filgotinib. |
| Certain adverse events, including cardiovascular-related adverse events, occurred more frequently in high-BMI subgroups. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.